Abstract
To determine the role of chemotherapy in the multi- disciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose mehtotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the <20% disease-free or over-all survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 21-26 |
| Number of pages | 6 |
| Journal | Journal of Clinical Oncology |
| Volume | 5 |
| Issue number | 1 |
| State | Published - 1987 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Adjuvant chemotherapy for osteosarcoma : A randomized prospective trial. / Eilber, F.; Giuliano, A.; Eckardt, J.; Patterson, K.; Moseley, S.; Goodnight Jr, James E.
In: Journal of Clinical Oncology, Vol. 5, No. 1, 1987, p. 21-26.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adjuvant chemotherapy for osteosarcoma
T2 - A randomized prospective trial
AU - Eilber, F.
AU - Giuliano, A.
AU - Eckardt, J.
AU - Patterson, K.
AU - Moseley, S.
AU - Goodnight Jr, James E
PY - 1987
Y1 - 1987
N2 - To determine the role of chemotherapy in the multi- disciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose mehtotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the <20% disease-free or over-all survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.
AB - To determine the role of chemotherapy in the multi- disciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose mehtotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the <20% disease-free or over-all survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.
UR - http://www.scopus.com/inward/record.url?scp=0023125939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023125939&partnerID=8YFLogxK
M3 - Article
C2 - 3543236
AN - SCOPUS:0023125939
VL - 5
SP - 21
EP - 26
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 1
ER -